Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) CFO Fawwad Qureshi sold 622 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $52.61, for a total transaction of $32,723.42. Following the completion of the sale, the chief financial officer now directly owns 9,867 shares in the company, valued at approximately $519,102.87. This trade represents a 5.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Trupanion Stock Performance
NASDAQ:TRUP traded down $0.85 during trading hours on Wednesday, hitting $53.50. 365,027 shares of the company traded hands, compared to its average volume of 677,237. The stock has a market capitalization of $2.27 billion, a price-to-earnings ratio of -167.19 and a beta of 1.69. Trupanion, Inc. has a twelve month low of $19.69 and a twelve month high of $57.90. The firm has a 50-day moving average of $49.50 and a 200 day moving average of $39.97. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.40.
Trupanion (NASDAQ:TRUP – Get Free Report) last released its earnings results on Wednesday, October 30th. The financial services provider reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.09. The firm had revenue of $327.50 million during the quarter, compared to analysts’ expectations of $321.79 million. Trupanion had a negative net margin of 1.08% and a negative return on equity of 4.36%. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.10) EPS. On average, analysts forecast that Trupanion, Inc. will post -0.23 EPS for the current year.
Hedge Funds Weigh In On Trupanion
Analyst Ratings Changes
A number of research firms recently weighed in on TRUP. Northland Securities increased their price objective on shares of Trupanion from $45.00 to $50.00 and gave the stock a “market perform” rating in a report on Thursday, October 31st. Bank of America lifted their target price on shares of Trupanion from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Friday, September 20th. Piper Sandler boosted their price objective on shares of Trupanion from $45.00 to $57.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Evercore ISI raised shares of Trupanion to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus lifted their target price on shares of Trupanion from $30.00 to $40.00 and gave the company a “hold” rating in a research note on Monday, September 23rd. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Trupanion has a consensus rating of “Moderate Buy” and an average target price of $44.67.
Check Out Our Latest Analysis on Trupanion
About Trupanion
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on a monthly subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other Business. It serves pet owners and veterinarians.
Featured Articles
- Five stocks we like better than Trupanion
- Consumer Staples Stocks, Explained
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Why is the Ex-Dividend Date Significant to Investors?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Calculate Options Profits
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.